- Ovulation induction:
- Step-up regimen: Initially SC/IM 37.5-75 units OD *14/7, then may increase by 37.5 units/day no more frequently than every week
- Max: 225 units/day
- Step-up regimen: Initially SC/IM 37.5-75 units OD *14/7, then may increase by 37.5 units/day no more frequently than every week
-
- Step-down regimen: SC/IM 150 units SC/IM OD until dominant follicle development, then decrease to 112.5 units/day *3/7, then decrease to 75 units/day
- Assisted reproductive technology:
- With no menotropins: Initially SC 225 units OD *5/7, then may adjust by up to 75-150 units/day no more frequently than every 2 days
- Max: 225 units/day for start dose, 450 units/day for subsequent doses
- With no menotropins: Initially SC 225 units OD *5/7, then may adjust by up to 75-150 units/day no more frequently than every 2 days
-
- With menotropins: Initially SC 75 units or 150 units OD *5/7, then may adjust dose by up to 75-150 units/day no more frequently than every 2 days
- Max: 225 units/day for total urofollitropin and menotropins start dose, 450 units/day for total combined subsequent doses
- With menotropins: Initially SC 75 units or 150 units OD *5/7, then may adjust dose by up to 75-150 units/day no more frequently than every 2 days
- Spermatogenesis induction (Off-label):
- Initially SC 150 units 3 times /week with hCG 3 times/week
- Max: 300 units 3 times/week
- May administer up to 18 months
- Initially SC 150 units 3 times /week with hCG 3 times/week
Injection: 75 units
For ART:
- Therapy should not exceed 12 days
- Consider adjusting the dose after 5 days based on ovarian response
- Do not make additional dosage adjustments more frequently than every 2 days or by >75 -150 IU at each adjustment
- Continue treatment until adequate follicular development is evident and then administer hCG
- Do not administer daily doses of urofollitropin or urofollitropin in combination with menotropins that exceed 450 IU
Human FSH; Gonadotropin
It stimulates ovarian follicular growth in women and spermatogenesis in men by stimulating FSH, which is responsible for normal follicular growth, gonadal steroid production, spermatogenesis and follicular maturation.
- Abdominal cramps
- Abdominal pain
- Headache
- Ovarian hyperstimulation syndrome
- Nausea
- Vaginal hemorrhage
- Ovarian cysts
- Pelvic pain
- Abdominal distension
- Pain
- URI
- Hot flashes
- Injection site reaction
- UTI
- Hypersensitivity to components
- Pregnancy
- Primary ovarian failure
- Uncontrolled thyroid disease
- Uncontrolled adrenal dysfunction
- Uncontrolled pituitary dysfunction
- Breast cancer
- Ovarian cancer
- Uterine cancer
- Hypothalamic tumor
- Pituitary tumor
- Organic intracranial lesion
- Abnormal uterine bleeding
- Non-PCOS-associated ovarian cyst
None remarkable
Drug Status
| Availability | Prescription only |
| Pregnancy | Category X |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Endogen HP | 75 IU | Injection | 2mL | Sanzyme Ltd C/O Surgilinks | Avacare Kenya |